Cargando…

Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis

INTRODUCTION: There is a renewed interest in the use of whole blood (WB) to manage patients with life-threatening bleeding. We aimed to estimate mortality and complications risk between WB and blood component therapy for haemostatic resuscitation of major bleeding. METHODS: We will conduct a systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Ssentongo, Anna E, Ssentongo, Paddy, Heilbrunn, Emily, Laufenberg Puopolo, Lacee, Chinchilli, Vernon M, Oh, John, Hazelton, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491282/
https://www.ncbi.nlm.nih.gov/pubmed/34607857
http://dx.doi.org/10.1136/bmjopen-2020-043967
_version_ 1784578708695154688
author Ssentongo, Anna E
Ssentongo, Paddy
Heilbrunn, Emily
Laufenberg Puopolo, Lacee
Chinchilli, Vernon M
Oh, John
Hazelton, Joshua
author_facet Ssentongo, Anna E
Ssentongo, Paddy
Heilbrunn, Emily
Laufenberg Puopolo, Lacee
Chinchilli, Vernon M
Oh, John
Hazelton, Joshua
author_sort Ssentongo, Anna E
collection PubMed
description INTRODUCTION: There is a renewed interest in the use of whole blood (WB) to manage patients with life-threatening bleeding. We aimed to estimate mortality and complications risk between WB and blood component therapy for haemostatic resuscitation of major bleeding. METHODS: We will conduct a systematic review and meta-analysis of studies published between 1 January 1980 and 1 January 2020, identified from PubMed and Scopus databases. Population will be patients who require blood transfusion (traumatic operative, obstetric and gastrointestinal bleeding). Intervention is WB transfusion such as fresh WB (WB unit stored for less than 48 hours), leukoreduced modified WB (with platelets removed during filtration), warm fresh WB (stored warm at 22°C for up to 8 hours and then for a maximum of an additional 24 hours at 4°C). The primary outcomes will be the 24-hour and 30-day survival rates (in-hospital mortality). Comparator is blood component therapy (red blood cells, fresh-frozen plasma and platelets given together in a 1:1:1 unit ratio). The Cochrane risk of bias tool for randomised controlled trials and Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) for observation studies will be used to assess the risk of bias of included studies. We will use random-effects models for the pooling of studies. Interstudy heterogeneity will be assessed by the Cochran Q statistic, where p<0.10 will be considered statistically significant and quantified by I(2) statistic, where I(2) ≥50% will indicate substantial heterogeneity. We will perform subgroup and meta-regression analyses to assess geographical differences and other study-level factors explaining variations in the reported mortality risk. Results will be reported as risk ratios and their 95% CIs. ETHICS AND DISSEMINATION: No ethics clearance is required as no primary data will be collected. The results will be presented at scientific conferences and published in a peer-reviewed journal.
format Online
Article
Text
id pubmed-8491282
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84912822021-10-14 Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis Ssentongo, Anna E Ssentongo, Paddy Heilbrunn, Emily Laufenberg Puopolo, Lacee Chinchilli, Vernon M Oh, John Hazelton, Joshua BMJ Open Surgery INTRODUCTION: There is a renewed interest in the use of whole blood (WB) to manage patients with life-threatening bleeding. We aimed to estimate mortality and complications risk between WB and blood component therapy for haemostatic resuscitation of major bleeding. METHODS: We will conduct a systematic review and meta-analysis of studies published between 1 January 1980 and 1 January 2020, identified from PubMed and Scopus databases. Population will be patients who require blood transfusion (traumatic operative, obstetric and gastrointestinal bleeding). Intervention is WB transfusion such as fresh WB (WB unit stored for less than 48 hours), leukoreduced modified WB (with platelets removed during filtration), warm fresh WB (stored warm at 22°C for up to 8 hours and then for a maximum of an additional 24 hours at 4°C). The primary outcomes will be the 24-hour and 30-day survival rates (in-hospital mortality). Comparator is blood component therapy (red blood cells, fresh-frozen plasma and platelets given together in a 1:1:1 unit ratio). The Cochrane risk of bias tool for randomised controlled trials and Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) for observation studies will be used to assess the risk of bias of included studies. We will use random-effects models for the pooling of studies. Interstudy heterogeneity will be assessed by the Cochran Q statistic, where p<0.10 will be considered statistically significant and quantified by I(2) statistic, where I(2) ≥50% will indicate substantial heterogeneity. We will perform subgroup and meta-regression analyses to assess geographical differences and other study-level factors explaining variations in the reported mortality risk. Results will be reported as risk ratios and their 95% CIs. ETHICS AND DISSEMINATION: No ethics clearance is required as no primary data will be collected. The results will be presented at scientific conferences and published in a peer-reviewed journal. BMJ Publishing Group 2021-10-04 /pmc/articles/PMC8491282/ /pubmed/34607857 http://dx.doi.org/10.1136/bmjopen-2020-043967 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Surgery
Ssentongo, Anna E
Ssentongo, Paddy
Heilbrunn, Emily
Laufenberg Puopolo, Lacee
Chinchilli, Vernon M
Oh, John
Hazelton, Joshua
Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
title Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
title_full Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
title_fullStr Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
title_full_unstemmed Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
title_short Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
title_sort whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491282/
https://www.ncbi.nlm.nih.gov/pubmed/34607857
http://dx.doi.org/10.1136/bmjopen-2020-043967
work_keys_str_mv AT ssentongoannae wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis
AT ssentongopaddy wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis
AT heilbrunnemily wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis
AT laufenbergpuopololacee wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis
AT chinchillivernonm wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis
AT ohjohn wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis
AT hazeltonjoshua wholebloodversuscomponenttherapyforhaemostaticresuscitationofmajorbleedingaprotocolforasystematicreviewandmetaanalysis